Nanoparticle compositions, methods of fabrication, and use for drug delivery
AssigneeDignity Health
InventorsRachael Sirianni, David Alexandro Medina, Eugene Chung
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition and use of the composition in the treatment of a disorder, for example, a neurological disease associated with retinoid signaling. The invention also includes the use of a retinoid encapsulated in nanoparticles. The retinoid encapsulated nanoparticles are adapted to increasing lifespan and conferring neuroprotective effects such as preserving motor units, reducing motor impairment, or reducing neuroinflammation in a subject.
Claims20
A therapeutic nanoparticle, comprising:
- a. a poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer comprising PLA having a number-average molecular weight of 9-23 kg/mole, and PEG having a number-average molecular weight of 0.5-10 kg/mole;
- b. a polymer, wherein the polymer is a short-chain polyester having a number-average molecular weight of 0.5-8 kg/mole;
- and
- c. a biologically active ingredient, wherein the zeta potential of the nanoparticle is between −50 and 20 mV.
A therapeutic nanoparticle, comprising:
- a. a poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer comprising PLA having a number-average molecular weight of 9-23 kg/mole, and PEG having a number-average molecular weight of 0.5-10 kg/mole;
- b. a polymer, wherein the polymer is a short-chain polyester having a number-average molecular weight of 0.5-8 kg/mole;
- and
- c. a biologically active ingredient, wherein the active ingredient has a partition coefficient (log P) of 2-10.
A therapeutic nanoparticle, comprising:
- a. a poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer comprising PLA having a number-average molecular weight of 9-23 kg/mole, and PEG having a number-average molecular weight of 0.5-10 kg/mole;
- b. a polymer, wherein the polymer is a short-chain polyester having a number-average molecular weight of 0.5-8 kg/mole;
- and
- c. a biologically active ingredient, wherein the active ingredient comprises a retinoid.
A therapeutic nanoparticle, comprising:
- a. a poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer comprising PLA having a number-average molecular weight of 15-17 kg/mole, PEG has a number-average molecular weight of 4-6 kg/mole;
- b. a polymer, wherein the polymer is a short-chain polyester having, and the short chain polyester has a number-average molecular weight of 2-5 kg/mole;
- and
- c. a biologically active ingredient.
Dependencies are inferred from the claim text.